BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+10.77%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.78B
AUM Growth
+$3.78B
(+9.1%)
Cap. Flow
+$24M
Cap. Flow
% of AUM
0.63%
Top 10 Holdings %
Top 10 Hldgs %
64.41%
Holding
33
New
1
Increased
14
Reduced
7
Closed
1
Top Buys
| 1 |
Exelixis
EXEL
|
$30.6M |
| 2 |
argenx
ARGX
|
$21.7M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$20.1M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$19.7M |
| 5 |
Nektar Therapeutics
NKTR
|
$19.5M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$32.4M |
| 2 |
CELG
Celgene Corp
CELG
|
$30.4M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$28.3M |
| 4 |
Neurocrine Biosciences
NBIX
|
$19.6M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$15.5M |
Sector Composition
| 1 | Healthcare | 96.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALDR
26
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $37.7M | 1% |
2,266,008
| – | – |
|
|
MYOK
27
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $33.3M | 0.88% |
510,000
+30,000
| +6% | +$1.96M |
|
|
GTHX
28
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $22.2M | 0.59% |
425,318
+72,711
| +21% | +$3.8M |
|
29
Novavax
NVAX
$1.2B
| $15.7M | 0.41% |
416,500
| – | – |
|
30
Cidara Therapeutics
CDTX
$1.61B
| $10.1M | 0.27% |
114,764
| – | – |
|
31
Scholar Rock
SRRK
$3.3B
| $4.89M | 0.13% |
+189,957
| New | +$4.89M |
|
|
ACHN
32
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $4.71M | 0.12% |
1,279,340
| – | – |
|
|
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-977,500
| Closed | -$15.5M |
|